Current Report Filing (8-k)
February 03 2020 - 8:39AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) January 31, 2020
Citius
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
|
333-206903
|
|
27-3425913
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
11
Commerce Drive, 1st Floor, Cranford, NJ
|
|
07016
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code (908) 967-6677
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
☐
|
Securities
registered pursuant to Section 12(b) of the Act:
|
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange
on
which registered
|
|
Common
stock, $0.001 par value
|
|
CTXR
|
|
The
Nasdaq Capital Market
|
|
Warrants
to purchase common stock
|
|
CTXRW
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
3.01.
|
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer or Listing.
|
As
previously reported, on October 30, 2019, Citius Pharmaceuticals, Inc., or the Company, received written notice from The Nasdaq
Stock Market, or Nasdaq, indicating that, because the closing bid price for the Company’s common stock had fallen below
$1.00 per share for 30 consecutive business days, the Company no longer complied with the $1.00 minimum bid price requirement
for continued listing on The Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules.
On
January 31, 2020, the Company received written notice from Nasdaq that the Company had regained compliance with Rule 5550(a)(2)
because the Company’s common stock had closed at a price greater than $1.00 for the 10 consecutive trading days between
January 16 and January 30, 2020. As a result, Nasdaq has closed the matter.
A
copy of the Company’s press release announcing the regaining of compliance with Rule 5550(a)(2) is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by reference herein.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
CITIUS PHARMACEUTICALS, INC.
|
|
|
|
|
Date:
February 3, 2020
|
/s/
Myron Holubiak
|
|
|
Myron
Holubiak
|
|
|
President
and Chief Executive Officer
|
2
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Apr 2023 to Apr 2024
